Prognostic value of long non-coding RNA MALAT1 in cancer patients
Metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) was identified to be the first long non-coding RNA as a biomarker of independent prognostic value for early stage non-small cell lung cancer patient survival. In recent years, the association between upregulated tissue MALAT1 level and incidence of various cancers including bladder cancer, colorectal cancer, and renal cancer has been widely discussed. The aim of our present study was to assess the potential prognostic value of MALAT1 in various human cancers. PubMed, Embase, Ovid, and Cochrane Library databases were systematically searched, and eligible studies evaluating the prognostic value of MALAT1 in various cancers were included. Finally, 11 studies encompassing 1216 participants reporting with sufficient data were enrolled in the current meta-analysis. The pooled hazard ratio (HR) was 2.05 (95 % confidence interval (CI) 1.64–2.55, p < 0.01) for overall survival (OS) and 2.66 (95 % CI 1.86–3.80, p < 0.01) for disease-free survival (DFS). In conclusion, high tissue MALAT1 level was associated with an inferior clinical outcome in various cancers, suggesting that MALAT1 might serve as a potential prognostic biomarker for various cancers.
KeywordsMetastasis associated in lung adenocarcinoma transcript 1 (MALAT1) Cancer Prognostic value
The work was funded by the National Natural Science Foundation of China (Grant nos. 31471297, 81302455, 81201557, 81373036).
Conflicts of interest
YW and DX have the right to grant on behalf of all authors and does grant on behalf of all authors. YW and WL contributed to conception and design of the study; WL, JX, and HZ contributed to conception, design, and editing the manuscript. All authors commented on drafts of the paper and have approved the final draft of the manuscript.
- 22.Ma KX, Wang HJ, Li XR, Li T, Su G, Yang P et al. Long noncoding RNA MALAT1 associates with the malignant status and poor prognosis in glioma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015. doi: 10.1007/s13277-014-2969-7
- 24.Pang EJ, Yang R, Fu XB, Liu YF. Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014. doi: 10.1007/s13277-014-2850-8
- 25.Schmidt LH, Spieker T, Koschmieder S, Schaffers S, Humberg J, Jungen D, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol. 2011;6(12):1984–92. doi: 10.1097/JTO.0b013e3182307eac.CrossRefPubMedGoogle Scholar
- 27.Zhang HM, Yang FQ, Chen SJ, Che J, Zheng JH. Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014. doi: 10.1007/s13277-014-2925-6
- 32.Li S, Wang Q, Qiang Q, Shan H, Shi M, Chen B et al. Sp1-mediated transcriptional regulation of MALAT1 plays a critical role in tumor. Journal of cancer research and clinical oncology. 2015. doi: 10.1007/s00432-015-1951-0
- 33.Wang X, Li M, Wang Z, Han S, Tang X, Ge Y et al. Silencing of long noncoding RNA MALAT1 by miR-101 and miR-217inhibits proliferation, migration and invasion of esophageal squamous cell carcinoma cells. The Journal of biological chemistry. 2014. doi: 10.1074/jbc.M114.596866